Evolus amends Daewoong supply pact: exits Russia, revamps Europe pricing

Evolus, Inc.

Evolus exits Russia; all rights to neurotoxin distribution revert to Daewoong.
European pricing changed from fixed transfer price to net-sales-based price with quarterly true-up.
Transfer price renegotiated annually; floor price per vial set.
Evolus must meet launch schedule and reporting obligations; failure allows Daewoong to revert pricing.
Parties to cooperate on transferring Russia regulatory materials to Daewoong.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Evolus, Inc. amended Fourth Amendment to License and Supply Agreement with Daewoong Pharmaceuticals Co., Ltd. (effective 2022-12-12).

Action: amendment
Agreement: license
Counterparty: Daewoong Pharmaceuticals Co., Ltd.
Effective: 2022-12-12

Exact text from the filing

On December 12, 2022, Evolus, Inc., a Delaware corporation (the “Company”), and Daewoong Pharmaceuticals Co., Ltd., a corporation organized and existing under the laws of the Republic of Korea (“Daewoong”) entered into a Fourth Amendment (the “Fourth Amendment”) to that certain License and Supply Agreement (the “Supply Agreement”), originally dated September 30, 2013, as amended.

View on SEC.gov

Browse all material agreements →

Evolus, Inc. filing history →

Source: SEC EDGAR

accession 0001570562-22-000149

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.